Collectively, these data confirm that GPA plays a pivotal role in mitigating hepatic steatosis and further imply an extended role beyond the liver in lipid accumulation, independent of its anti-inflammatory character at the early stage of NAFLD. Here, GYPA is linked to metabolic dysfunction-associated steatotic liver disease.